Alector, Inc. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. Alector is a clinical-stage biopharmaceutical company developing immuno-neurology therapies; it has no approved products and no product-sale revenue. Amounts below are in millions of dollars unless otherwise noted.
Financial performance and liquidity
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Collaboration revenue | $79.9 | $6.6 | $104.3 | $10.7 |
| Research and development expense | $54.5 | $47.8 | $107.6 | $93.6 |
| General and administrative expense | $15.8 | $14.1 | $31.4 | $25.1 |
| Operating income (loss) | $9.5 | $(55.3) | $(34.6) | $(108.0) |
| Net income (loss) | $9.9 | $(55.1) | $(34.7) | $(107.3) |
| Operating cash flow | Not separately presented | Not separately presented | $77.6 | $(97.2) |
Q2 operating and net margins were approximately 11.9% and 12.4%, respectively; these figures reflect collaboration revenue recognition, not product sales. Six-month net loss per share was $0.42, compared with $1.35 in the prior-year period.
At June 30, 2022, cash and cash equivalents were $172.3 and marketable securities were $636.6, totaling $808.9 in cash, cash equivalents, and marketable securities. Current assets were $827.0 versus current liabilities of $149.4. Total liabilities were $601.2, including $45.5 of operating lease liabilities and $520.9 of deferred collaboration revenue. The filing reports no borrowings or financial debt. Accumulated deficit was $481.1.
Six-month operating cash flow was positive primarily because deferred revenue increased $95.7, including the $200 million GSK payment received in January 2022; it should not be interpreted as recurring operating cash generation. Investing cash outflow was $237.9, mainly reflecting purchases of marketable securities.
Changes versus prior period and significant items
- Q2 collaboration revenue rose $73.3 year over year, while operating expenses increased $8.5. The company moved from a $55.1 Q2 2021 net loss to $9.9 net income.
- Of Q2 2022 collaboration revenue, $58.6 came from AbbVie and $21.3 from GSK. The AbbVie amount included a net revenue increase associated with revised estimated costs after AL003’s termination, partially offset by higher expected AL002 costs.
- Six-month R&D expense increased $14.0, primarily from personnel, stock compensation, facilities, and early-stage programs. G&A increased $6.3, mainly from personnel-related costs and growth-support expenses.
- Unrealized losses on marketable securities were $5.3 for the first half of 2022 and were recorded in other comprehensive loss, not earnings. The company reported no credit-related investment losses.
Outlook, development updates, and risks
- Management estimated existing cash, cash equivalents, and marketable securities would fund operations and capital expenditure requirements into at least the second half of 2024, based on assumptions that may prove inaccurate. The company expects expenses to increase and may seek additional financing.
- Latozinemab is in the pivotal Phase 3 INFRONT-3 trial for FTD-GRN. The company reported prior encouraging biomarker and clinical signals, but these are not confirmatory pivotal-trial results.
- In the AL002 Phase 2 Alzheimer’s trial, ARIA cases occurred, including a small number of serious adverse events in APOE e4/e4 homozygotes. Dosing and enrollment of this genotype were discontinued; a further protocol amendment to exclude them was planned. Enrollment timing impact remained under assessment, with MRI monitoring and independent monitoring in place.
- AbbVie formally terminated the AL003/CD33 program on June 30, 2022, citing insufficient evidence of an effect on pharmacodynamic biomarkers in Phase 1. Alector will not receive future milestones for that program.
- AL101 Phase 1 additional-dose data were expected in Q4 2022. Alector expected to initiate a first-in-human AL044 trial in the second half of 2022. It planned to re-acquire AL008 rights from Innovent, which would not continue development, and said AL009 could enter clinical studies within the next year.
- Alector and GSK made a strategic, non-safety decision to close enrollment in the latozinemab ALS Phase 2 study while evaluating a potential broader Phase 2b study. COVID-19-related site and scheduling disruptions could affect trial conduct and data quality.
- Key risks include clinical efficacy and safety uncertainty, trial enrollment and delays, reliance on partners and third-party manufacturers, funding needs, inflation and hiring costs, and regulatory, intellectual-property, and competitive risks. Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Whether the reported cash runway through at least the second half of 2024 remains achievable as trial spending, inflation, and program priorities evolve.
- How collaboration revenue recognition—especially the AbbVie estimate adjustment and deferred-revenue release—affects reported quarterly earnings and cash-flow interpretation.
- INFRONT-3 progress and eventual results, and the safety, enrollment, and timing consequences of ARIA-related changes in INVOKE-2.
- Timing and results of AL101, AL044, and AL009 development, plus the practical and financial implications of recovering AL008 rights from Innovent.
- The terms and performance of the GSK and AbbVie collaborations, including cost-sharing obligations, milestones, and the remaining deferred-revenue recognition periods.